HDACIvir´s- Novel anticancer agents

The Invention The research teams at Tel Aviv and Bar Ilan Universities have developed novel compounds derived from known histone deacetylase inhibitory (HDACI) molecules linked to acyclovir and its analogs. The new compounds (HDACIvir's) demonstrated potent anticancer activity both in vitro and in vivo and were well tolerated in initial safety studies The Need According to WHO reports, cancer is the leading cause of death worldwide - it accounts for 7.6 million (or 13%) from all deaths worldwide in 2005.

Cytotoxic drugs are the mainstays of therapeutic regimens and play a major role in the treatment of cancers. However, new therapies, working via novel mechanisms are desperately required Advantages Simple, straight forward synthesis Abounded and simple raw materials Unique mechanism of action which includes HDAC inhibition as well as potentially inhibition of DNA synthesis The compounds are well tolerated in initial toxicology studies
Stage A series of compounds were synthesized and a lead compound has been identified showing strong HDAC inhibitory activity along with potent anticancer activity. The biological activity has been shown in vitro using human glioblastoma and prostate carcinoma cell lines as well as in vivo in Lewis lung carcinoma and 4T1 breast carcinoma animal models. Initial safety studies with the lead compound (acute single dose) gave an LD50 value of over 750 mg/kg while efficacy was achieved at 40 mg/kg

Patents:
US 60,920,820

Type of Offer: Licensing



« More Pharmaceutical Patents

---